Market capitalization | $94.13m |
Enterprise Value | $-70.21m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.62 |
P/B ratio (TTM) P/B ratio | 0.51 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-135.87m |
Free Cash Flow (TTM) Free Cash Flow | $-113.36m |
Cash position | $189.31m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
4 Analysts have issued a HilleVax forecast:
4 Analysts have issued a HilleVax forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -3.07 -3.07 |
17%
17%
|
|
EBITDA | -133 -133 |
18%
18%
|
EBIT (Operating Income) EBIT | -136 -136 |
17%
17%
|
Net Profit | -150 -150 |
39%
39%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.
Head office | United States |
CEO | Robert Hershberg |
Employees | 90 |
Founded | 2020 |
Website | www.hillevax.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.